Secondary Analysis of the BETR-D study: lower incidence of MDROs, hospital-wide
Using the same data as the Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study, researchers did a secondary analysis of the BETR-D study, which showed that enhanced terminal room disinfection with Tru-D SmartUVC can lead to a decrease in the incidence of targeted multidrug-resistant organisms (MDROs) such as C. diff and VRE for all patients, hospital-wide. Individual hospital results may vary.
The secondary analysis, Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomized controlled trial with crossover design (BETR Disinfection), which was published in The Lancet Infectious Diseases, discusses the prescribed secondary analysis of the BETR-D randomized clinical trial.
This secondary analysis of the BETR-D study showed that with an enhanced, terminal room UVC disinfection program in place, the entire hospital environment can be safer. Regardless of whether the room was previously occupied with a patient who had an MDRO, or whether or not they had been previously colonized, if you add a structured, targeted UVC disinfection program to your cleaning protocols and a high compliance of manual cleaning, your hospital may have fewer incidences of C. diff and VRE.
The BETR-D Research Team concluded that, “…Enhanced terminal room disinfection with UV in a targeted subset of high-risk rooms (ie, contact precaution rooms) led to a decrease in risk of acquisition of target multidrug-resistant organisms such as C. difficile and VRE for all hospitalised patients, through both direct and indirect effects.”
Stay tuned to learn more about the lessons learned from the BETR-D study. If you have questions about the study or Tru-D’s technology, e-mail us at firstname.lastname@example.org.